Close menu

August 31st, 2021 | 10:37 CEST

Sales explosion? Novavax and Diamcor on the trail of BioNTech

  • Diamonds
Photo credits:

When companies suddenly report strong jumps in sales, investors should take a closer look. On the one hand, there may be considerable opportunities for share price gains. On the other hand, it must also be checked whether the development is sustainable or whether it is a one-off or seasonal event. BioNTech has impressively shown that the Company and the share can profit from a sudden increase in sales. Who is next? Investors should take a closer look at the vaccine developer Novavax and the diamond producer Diamcor - it could be worthwhile.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: NOVAVAX INC. DL-_01 | US6700024010 , Diamcor Mining Inc. | CA2525312070 , BIONTECH SE SPON. ADRS 1 | US09075V1026

Table of contents:

    Diamcor Mining wants to double sales: In the slipstream of De Beers and Tiffany

    Diamcor Mining is still largely unknown on the German capital market. But this could change quickly. The Canadian Company has started to develop its Krone Endora mine. It is located in a well-known diamond district in South Africa and borders directly on one of the most productive mines in the world - the Venetia mine of the De Beers Group. Therefore, the luxury group Tiffany has already bought into Diamcor Mining through a subsidiary. For EUR 10 million (partly loan, partly convertible bond), Tiffany has secured a right of first refusal on rough diamonds at a fair market price. And Diamcor has now started production. As of July 2021, the Canadians have mined 2,989.54 carats of diamonds, generating revenue of CAD 744,085. The production volume is expected to double in the coming months. At the same time, only 5% of the area has been mined so far. The remaining 95%, therefore, offers further considerable growth potential.

    After a significant price increase between the end of May and July, the share has since consolidated between CAD 0.35 and CAD 0.27. However, this could soon be over. If monthly sales can be increased to over CAD 1.4 million, the CAD 18 million does not seem too high. Especially since only 5% of the property is currently being worked. With the revenue from diamond sales, Diamcor could develop other parts of the Krone Endora project.

    BioNTech uses billions from Corona vaccine for research

    BioNTech is currently demonstrating that it is possible to use a relatively short-term sales boom to take the entire Company into a new league. Before the Corona pandemic, BioNTech employed around 1,300 people; now, it has approximately 2,000 - and is currently looking for another 500. The billions in revenue from the sale of the COVID-19 vaccine are being invested in broadening the Company's base. The Marburg-based Company is researching other vaccines based on mRNA technology against the dangerous tropical disease malaria. A clinical trial is to be launched by the end of 2022. The project is supported by the EU Commission and the WHO. In addition, BioNTech recently announced the acquisition of Kite's neoantigen T-cell receptor (TCR) development platform for solid tumors and clinical product candidate manufacturing assets, including leases for the manufacturing facility in Gaithersburg USA. With the acquisition, BioNTech expands its manufacturing capabilities in North America and aims to accelerate its research and development programs for individualized neoantigen TCR cell therapies for solid tumors. Growth financing should not be a problem for the foreseeable future. The COVID-19 Delta variant continues to keep the world on tenterhooks. Infections and deaths are skyrocketing again, and not just in the US. As a result, the BioNTech vaccine will remain a cash cow for the foreseeable future.

    Novavax: The clock is ticking for the vaccine

    Due to the current Corona situation, Novavax does not seem to be late with its NVX-CoV2373 vaccine either. The vaccine promises a significant increase in sales for the US company. Therefore, the Company and the share are facing important weeks. The specific date for when the Americans will apply for approval of their vaccine in the EU is still open. However, to receive it by the end of the year, experts believe it should be done by October. In addition, if Novavax gets a grip on the problems with production partners in the US, this should give the stock a boost again. It will be important that the mass-produced vaccine is identical to the vaccine from the clinical trials. In the UK, at least, plans already seem to be in place for the Novavax vaccine. Along with products from BioNTech and Moderna, it is part of a government study around the effect of booster vaccines. The data from 1,200 study participants are to be evaluated before the end of the year.

    BioNTech is setting an example of how to use strongly rising sales to develop the Company sustainably. Diamcor wants to follow this example - albeit in a completely different industry - and use the increased cash flow from diamond sales for project expansion. Novavax currently still has the most question marks, but the Delta variant seems to ensure that the vaccine is not too late.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author

    Related comments:

    Commented by Fabian Lorenz on January 6th, 2022 | 11:26 CET

    The beginning of the end at BioNTech? Positive start for JinkoSolar and Diamcor

    • Diamonds

    Is Omicron the beginning of the end of the Corona pandemic? Not only stock market players are asking themselves this question. Because as it seems, the virus variant is more contagious but seemingly leads to less severe sickness. As a result, the shares of vaccine manufacturers such as BioNTech, Moderna and Valneva have recently suffered. However, there are positive things to report, especially for BioNTech. While the Mainz-based Company is optimizing its vaccine for the Omicron variant, there is also positive news from the USA. Not only the COVID-19 vaccine is in demand worldwide, but also diamonds. Most recently, Israel reported a significant increase in demand. Tiffany & Co. partner Diamcor is benefiting from this demand. JinkoSolar's share price is heading north again in the first few days of trading after the heavy losses before Christmas. The IPO of the subsidiary is taking shape.


    Commented by Stefan Feulner on January 3rd, 2022 | 08:50 CET

    BYD, Diamcor, LVMH - Impressive growth

    • Diamonds

    Despite the Corona pandemic, travel bans and closed stores due to several lockdowns, demand for luxury goods continues unabated. Now add rising inflation to the mix. Tangible assets such as shares, precious metals and jewelry are the best protection against currency devaluation. The purchase of diamonds is growing in popularity. The choice of listed companies on the stock exchange is small.


    Commented by André Will-Laudien on December 20th, 2021 | 12:39 CET

    Porsche, Diamcor Mining, Aston Martin, Gucci - Who wants to do without luxury?

    • Diamonds

    The Ridley Scott film "House of Gucci" is currently running very successfully in German cinemas. The film's plot shows the disintegration of the Tuscan family dynasty, which is said to have happened in this or a similar way: Gucci has been writing bad numbers for years, is considered old-fashioned and outdated. The two company owners refuse fundamental renewals and stumble at the economic changes in the 1980s. The family runs into tax problems and inheritance disputes and ultimately fails to keep the group going. But the brand is strong, and a takeover by investors from abroad is quickly on the cards. So nothing stands in the way of the transformation of the House of Gucci. A film worth seeing about rising, world fame, mismanagement and decay. Many stock market stocks run in similar cycles; luxury stocks, in particular, are very susceptible to fads, but they also hold their value.